SHARE

GSK to invest $30bn in US R&D and supply chain over five years

GSK will allocate $30bn to expand its US research, manufacturing, and digital capabilities through 2029. The plan includes a $1.2bn biologics facility in Pennsylvania and upgrades to five existing sites, supporting life sciences innovation.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.